Review articlePublished 29 Aug 2022
Sacubitril/valsartan: a new antihypertensive drug in the future?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hypertension is one of the leading epidemic factors of cardiovascular and cerebrovascular disease around the world. Many researchers have found that Sacubitril/Valsartan, the single angiotensin receptor-neprilysin inhibitor, played a critical role in lowering hypertension. However, Sacubitril/Valsartan’s indications and usage for hypertension has not been accepted in the world, except for China. The mechanism of Sacubitril/Valsartan’s antihypertensive effect is clear, including inhibiting renin-angiotensin system and reducing natriuretic peptides’ degradation. In this article, we retrieved and reviewed all clinical studies that explored the effect of Sacubitril/Valsartan or its safety in the treatment of hypertension patients. Most studies concluded that in comparison with traditional antihypertensive drugs (mainly including angiotensin receptor blockers or amlodipine), Sacubitril/Valsartan was firmly effective and safe. Thus, we deduce that Sacubitril/Valsartan’ indication for hypertension will be paid more attention and may be included in guideline for hypertension soon.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Drug Abuse
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Guan Xuehao”
- BylineArticles whose byline prints “Zhang Rui”
- BylineArticles whose byline prints “Zhang Guangfang”
- BylineArticles whose byline prints “Wang Jian”
- BylineArticles whose byline prints “Wang Shuguang”
- BylineArticles whose byline prints “Liu Baoshan”
- BylineArticles whose byline prints “Zhang Aiyuan”